Rheumatology Department, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S139-61. Epub 2012 May 11.
To provide recommendations on behalf of the Italian Society for Rheumatology for the off-label use of biologic agents in the treatment of large-vessel vasculitis.
A panel of experts performed a literature search and selected the evidence relevant to the topic. The following five large-vessel vasculitides were considered: giant cell arteritis, Takayasu arteritis, primary angiitis of the central nervous system, Cogan's syndrome, and Adamantiades-Behçet's disease.
A consensus was achieved regarding the indication of biologic agents for the treatment of large-vessel vasculitis. Levels of evidence were assigned to the papers retrieved, and the strength of the recommendations was graded according to the levels of evidence.
These recommendations may be used for guidance in deciding which patients with large-vessel vasculitis should receive biologic therapy. Further updates of these recommendations may be published on the basis of the results of new clinical studies and of data from post-marketing surveillance.
代表意大利风湿病学会就生物制剂在治疗大血管血管炎中的超适应证使用提供建议。
专家组进行了文献检索，并选择了与该主题相关的证据。考虑了以下五种大血管血管炎：巨细胞动脉炎、Takayasu 动脉炎、原发性中枢神经系统血管炎、Cogan 综合征和 Adamantiades-Behçet 病。
就生物制剂治疗大血管血管炎的适应证达成了共识。为检索到的论文分配了证据水平，并根据证据水平对建议的强度进行了分级。
这些建议可用于指导决定哪些大血管血管炎患者应接受生物治疗。根据新的临床研究结果和上市后监测数据，可能会发布这些建议的进一步更新。
